Podcasts about crispr cas9

Maria shares insights into the concerning reality of the transhumanist agenda being actively pursued by governments and corporations. She explains that transhumanism, often dismissed as conspiracy, is in fact a very real and alarming movement with tangible plans to reshape humanity. Through her meticulous microscopic research, Maria uncovers disturbing evidence of contaminants and foreign materials in COVID-19 vaccines, suggesting a sinister agenda beyond just public health She cautions that this information should be approached carefully, as those revealing these truths have faced serious consequences. Maria's work aims to empower people with knowledge to make informed decisions and take action against this emerging threat to our humanity. According to the speaker, we are in the midst of a concerning transition that humanity did not ask for The speaker believes there is a concerted effort to transform and harvest humans, as evidenced by the introduction of inorganic blood contaminants and other threats to our health and well-being. The speaker urges the audience to be vigilant and resist these efforts, as the human body and genome are incredible and worth preserving. They raise alarming questions about population declines, poisoning, and the emergence of different human species, calling for action to break free from this biological and spiritual battle The speaker discusses the alarming capabilities of nanoparticles and microrobots, which can be programmed for surveillance, drug delivery, and even self-replication using DNA. They warn that these advanced technologies, which can interface with mobile phones and satellites, are already being deployed and can monitor individuals from within their own bodies. The speaker emphasizes the complex physics behind these particles, their ability to adapt to environmental factors, and the potential dangers they pose to unsuspecting individuals The speakers discuss the use of silicone-encapsulated nanoparticles and hydrogels in various medical and scientific applications. These include gene editing with CRISPR-Cas9, tracking genetically engineered microorganisms, delivering growth factors for tissue engineering, and creating biosensing platforms. The speakers highlight the complexity of these materials and the importance of understanding how they interact with the human body They caution about the potential risks and emphasize the need for thorough testing and evaluation to ensure the safety and efficacy of these emerging technologies. The speaker discusses their research into nanoparticles and bioengineered materials that appear to be self-replicating and overwhelming people's immune systems. They describe seeing fibers, hydrogels, and other complex structures forming, and how these substances can integrate with the body in harmful ways, leading to organ damage and the surge of certain cancers The speaker also raises concerns about a "Florida fog" that contained toxic chemicals like platinum and styrene, making people sick. They emphasize the importance of understanding these emerging threats to public health and the need to find ways to eliminate these dangerous particles from the body. The speaker discusses their concerns about chemicals potentially being dispersed through atmospheric phenomena like fog They describe analyzing samples and finding high levels of metals like platinum, as well as compounds like polyethylene glycol that are used in various technologies. The speaker believes these elements may be intentionally introduced to increase reaction rates and yields for certain processes. They also note concerning health effects like muscle weakness that can arise from exposure to these substances Overall, the speaker is deeply worried about the potential impacts of these mysterious dispersed materials on people's health and the environment. The speaker shares their concerning observations about changes in weather patterns and the presence of unusual particles and fibers in snow and blood samples. They describe finding substances like thallium, platinum, yttrium, silicone, and bromine, as well as fiber-like structures that appear to be tethering white blood cells together The speaker suggests these fibers may be part of a "synthetic biology" system that is harvesting electrons and disrupting the electrical charge of the blood. They express alarm at these findings and their potential implications for human health. The speakers discuss the concerning presence of synthetic materials, such as silicone, platinum, and tellurium, in human blood samples, both injected and uninjected They describe how these materials can form fiber-like structures that become superconductive, potentially allowing them to take over the body. The speakers warn that this proliferation of synthetic materials is happening regardless of whether someone has received injections, and that eventually the body will become overwhelmed. They emphasize the need to understand how these materials are using our biology against us, highlighting the role of chlorine in the white blood cell response as particularly important The speaker describes their shocking discovery of what they call "Hydra" - a complex, multi-material structure that grew within the blood of a person who had received two Pfizer vaccine doses. The speaker expresses fear and concern over the apparent indestructibility of this structure, which they believe is part of a broader phenomenon of strange fibrous formations appearing in people's blood and bodily fluids post-vaccination. The speaker emphasizes the need to proactively detoxify the body, particularly through infrared saunas and lymphatic drainage, in order to eliminate the silicone and other metals that seem to be accumulating in the body Overall, the speaker shares a deeply troubling finding that they believe warrants urgent investigation and action. The speakers delve into the concerning issue of geoengineering and the contamination of our environment with synthetic materials like silicone, bromine, tellurium, and zirconium. These nanoparticles are found in our food, water, soil, and air, and can severely impact our health, causing inflammation, DNA damage, and organ toxicity The speakers emphasize the need to understand how these materials interact with electromagnetic fields and are used in various technologies, from biosensors to soft robotics. They urge the audience to be aware of the far-reaching consequences of this environmental pollution and the importance of keeping these harmful substances out of our bodies. The speaker discusses the concerning implications of new technologies being introduced into the human body, such as soft robotics, silicon nanoparticles, and strontium contamination They express worries that these substances are transforming people into "transhuman entities" and causing issues like young children needing frequent blood transfusions. The speaker believes many people who have received injections may not survive long-term, as their cells become synthetic and vulnerable to diseases and parasites. Overall, the speaker paints a dystopian picture of the potential risks of these emerging technologies being integrated into the human body The speaker expresses deep concerns about a potential dystopian future where a fungal pathogen causes a mass human die-off, and survivors are either transformed into controllable "transhumans" or face shortened lifespans and social credit-based discrimination. They believe the younger generation, particularly those aged 18-30, are the primary targets. The speaker cites evidence of genome integration and parasitic infestations, warning that those who did not take the injection may be overcome by the aggressive reactivity of their biology They also believe that the spraying of substances is affecting people's minds, leading to strange and uncontrolled behaviors. The speaker advocates for maintaining one's wits and discernment in these challenging times, but remains convinced that their insights are real and true, and that the situation can be broken down and understood. The speakers discuss the challenges of removing harmful substances like lanthanides and rare earth metals from the body, which are found in vaccines and other medical products They suggest using a combination of natural and synthetic remedies, such as EDTA, methylene blue, and DMSO, to help chelate and remove these toxins. However, they caution that the process must be done carefully and in the right order, using toxin binders to prevent reaccumulation. The speakers also highlight how these metals are used in various products, including hydrogels and GMO foods, to stabilize them, making them difficult to break down They propose using enzymes like cellulase to disrupt the gel structure and remove the lanthanide hydrogels from the body. The speakers are discussing the complex science behind quantum computing, superconductors, and advanced physics used in synthetic biology. They describe the use of lanthanide-doped nanocrystals that can undergo photon upconversion, a process that generates energy in a continuous loop The speakers warn that these technologies are being used against us, potentially building neural networks inside human beings. They emphasize the dangers of these advanced physics applications and the need to understand the mechanisms involved. The speaker discusses their findings about the presence of various metals, including yttrium and thallium, in the human body and their concerning implications They explain how these metals can bind to chlorine, form hydrogels, and act as battery packs and computers within the body, potentially contributing to the development of synthetic beings. The speaker also highlights the lack of regulation and oversight in the biomedical industry's use of these nanomaterials, urging listeners to take action against the government agencies that enable this concerning practice. The speaker shares their extensive research into combating the synthetic contaminants and technological transformations that they believe are being used to control and exploit humanity They have developed a product called Novolytic, which aims to oxidize and break down harmful hydrogels, protect against DNA integration, remove synthetic and zombie cells, and prevent the formation of superconductive fibers and self-replicating nanoparticles. The speaker believes Novolytic can help people lead an asymptomatic life and feel safe, though they emphasize it is not a cure. Their goal is to resist the transformation of humanity into a "cyborg reality" and empower people to partner with their own bodies to remove these synthetic contaminants The speakers discussed a revolutionary approach to protecting telomeres, the protective caps at the ends of DNA strands. They have developed a natural supplement called Insulis that has shown the ability to not only maintain but even increase telomere length, even in individuals who have received COVID-19 vaccines. The speakers, including Dr Group of Global Healing, are partnering to manufacture and distribute this product widely to help people combat the potential negative impacts of the vaccines. Their goal is to provide a safe, natural solution that can empower people to take control of their health and fight back against synthetic threats. In this podcast dialogue, the speakers discuss groundbreaking research and innovations aimed at helping humanity One speaker, an expert in quantum hematology, believes that the rush to implement Agenda 2030 is driven by fear of human consciousness and its powerful electrical and vibrational effects. They suggest that by remediating and reconnecting with each other, and healing our gut health, we can find a way to stop the "garbage" and elevate as a race. The speakers are passionate about sharing this transformative information and encourage the audience to visit their website, Abaytonaturals com, to learn more.

Emmanuelle Ducros nous raconte une histoire digne d'un film de science-fiction. Une entreprise de biotechnologie de la Silicon Valley, Colossal Biosciences, a réussi à ressusciter une espèce de loup géant éteinte depuis 13 000 ans : le loup sinistre.Après avoir obtenu de l'ADN de cette créature disparue, l'entreprise a utilisé la technologie d'édition génomique CRISPR-Cas9 pour modifier le génome d'un loup moderne et recréer les caractéristiques du loup sinistre. Le résultat est surprenant : deux jeunes loups, Romulus et Remus, et une petite femelle nommée Khaleesi, sont aujourd'hui en vie dans une réserve tenue secrète.Mais cette prouesse technologique soulève de nombreuses questions. À quoi servent ces animaux ressuscités ? Des attractions de zoos ? Un moyen de se donner bonne conscience sur les extinctions actuelles ? Emmanuelle Ducros analyse les enjeux éthiques et les dérives potentielles de cette expérience de "Jurassic Park dans la Silicon Valley".Au-delà du loup sinistre, Colossal Biosciences envisage également de faire renaître d'autres espèces emblématiques, comme le mammouth laineux ou le dodo. Mais cette science du spectacle ne risque-t-elle pas de détourner l'attention des véritables enjeux de la préservation de la biodiversité ?Cet épisode vous invite à réfléchir sur les limites de la technologie et les dérives potentielles de l'hybris humaine. Ne manquez pas cette analyse incisive et originale de "Voyage en Absurdie" !Notre équipe a utilisé un outil d'Intelligence artificielle via les technologies d'Audiomeans© pour accompagner la création de ce contenu écrit.Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Imagine your doctor could precisely predict your personal risk of disease, diagnose the cause of illness with pinpoint accuracy when it did occur, and develop an effective treatment plan with low side effects the first time, rather than through trial and error. That's the promise of personalized medicine. And it would be a revolution in healthcare. At the heart of this vision is the notion that our genetic differences have a big impact on how each of us responds to disease and treatment. To realize a future of personalized medicine then, we need to understand and investigate just how genetic variations, including mutations, contribute to illness and respond to doctors' attempts to address it. But how can scientists do that efficiently with a human genome that spans about three billion base pairs of DNA across tens of thousands of genes? That's where the work of PhD student Dawn Chen comes in. A student in Harvard's Department of Stem Cell and Regenerative Biology and the Systems, Synthetic, and Quantitative Biology Program, Chen was named a recipient of the 2025 Harold M. Weintraub Graduate Student Award for Outstanding Achievement and Exceptional Research in the Biological Sciences, presented by Seattle's Fred Hutch Cancer Center. With her colleagues in the lab of Harvard professor Fei Chen, Dawn Chen is developing an innovative gene-editing tool known as helicase-assisted continuous editing, or HACE. A breakthrough in genetic engineering, supported in part by funds from the National Institutes of Health, HACE makes edits to specific genes, allowing researchers to investigate how genetic variations contribute to disease. The technique could lead to the identification of specific mutations that influence the effectiveness of drugs and therapies for illnesses like cancer. 

Plongez dans l'univers fascinant et controversé de CRISPR-Cas9, une technique de modification génétique qui promet de révolutionner la médecine. Entre espoirs de guérison et risques éthiques, découvrez les enjeux de cette innovation révolutionnaire.La tech entre les lignes, la chronique qui décrypte les articles tech, animée par Louis de Diesbach.   ***** À PROPOS DE TRENCH TECH *****LE talkshow « Esprits Critiques pour Tech Ethique »Écoutez-nous sur toutes les plateformes de podcast

In this episode of Going anti-Viral, Dr Michael Saag speaks with Dr Joseph Eron, Professor of Medicine at University of North Carolina (UNC) about the topic of his upcoming presentation at the Conference on Retroviruses and Opportunistic Infections (CROI) 2025: HIV Cure Research: State of the Art and Navigating Presentations at CROI 2025. Dr Eron discusses the state of HIV cure research including a detailed discussion of why it has been so difficult to develop a cure for HIV. Dr Saag and Dr Eron discuss the difference between HIV cure and functional cure and provide a detailed overview of cure research efforts looking at blocking and locking HIV in human DNA. Dr Saag and Dr Eron also discuss the potential for “molecular scissors” (CRISPR-Cas9) to cure HIV. Finally, they provide an overview of cure research that will be presented at CROI, highlighting the plenary presentation by Dr Ole Søgaard at CROI on Monday March 10 entitled HIV Cure: A Translational Research Perspective. For more information about the topic of this episode, listen to an earlier episode of Going anti-Viral where Dr Saag discusses Vaccine Development with Dr Richard Koup, see links in the resources below. 0:00 – Introduction1:31 – Defining cure in the context of HIV4:56  – Why is it so hard to cure HIV7:56 – What is functional cure11:47 – Description of the concept of “block and lock” in human DNA14:33 – Discussion of tat inhibitors – blocking of HIV regulatory genes18:02 – Prospect of using “molecular scissors” (CRISPR-Cas9) as a cure23:13 – Highlights in HIV cure research at CROI and closing remarksResources: CROI 2025: https://www.croiconference.org/Going anti-Viral Episode 4 – A Deep Dive into Vaccine Development with Dr Richard Koup: Apple Podcasts: https://podcasts.apple.com/us/podcast/episode-4-a-deep-dive-into-vaccine-development-with/id1713226144?i=1000637677124 YouTube: https://youtu.be/nXeMt3GMj4Q __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

CardioNerds Cardiac Amyloidosis Series Chair Dr. Rick Ferraro and Episode Lead Dr. Anna Radakrishnan discuss the biology of transthyretin amyloid cardiomyopathy (ATTR-CM ) with Dr. Daniel Judge.  Notes were drafted by Dr. Anna Radakrishnan. The audio was engineered by student Dr. Julia Marques.  This episode provides a comprehensive overview of transthyretin (ATTR) cardiac amyloidosis, a complex and rapidly evolving disease process. The discussion covers the key red flags for cardiac amyloidosis, the diagnostic pathway, and the implications of hereditary versus wild-type ATTR. Importantly, the episode delves into the current and emerging therapies for ATTR, including stabilizers, gene silencers, and promising treatments like CRISPR-Cas9 and antibody-based approaches. Dr. Judge shares his insights and excitement about the rapidly advancing field, highlighting the need for early diagnosis and the potential to improve long-term outcomes for patients with this condition.  Enjoy this Circulation Paths to Discovery article to learn more about the CardioNerds mission and journey.  US Cardiology Review is now the official journal of CardioNerds! Submit your manuscripts here.  CardioNerds Cardiac Amyloid PageCardioNerds Episode Page Pearls: - Biology of Transthyretin amyloid cardiomyopathy Maintain a high index of suspicion! Look for subtle (yet telling) signs like ventricular hypertrophy, discordant EKG findings, bilateral carpal tunnel syndrome, and spontaneous biceps tendon rupture.  Utilize the right diagnostic tests. Endomyocardial biopsy remains the gold standard, but non-invasive tools like PYP scan with SPECT imaging and genetic testing are essential for accurate diagnosis.  Differentiating hereditary from wild-type ATTR is critical, as genetic forms may have a more aggressive course and familial implications.  Early diagnosis and intervention significantly improve prognosis, making vigilance in screening and prompt treatment initiation essential.  The future is now! Cutting-edge therapies are transforming the treatment landscape, including TTR stabilizers, gene silencers, and emerging technologies like CRISPR-Cas9 and antibody-based treatments.  Notes - Biology of Transthyretin amyloid cardiomyopathy What is transthyretin amyloid (aTTR) and how is it derived?  Transthyretin (TTR) is a transport protein primarily synthesized by the liver, responsible for carrying thyroid hormones (thyroxine) and retinol (vitamin A) in the blood. It circulates as a tetramer, composed of four identical monomers, which is essential for its stability and function.  In transthyretin amyloid (ATTR) amyloidosis, the TTR protein becomes unstable, leading to its dissociation into monomers. These monomers misfold and aggregate into insoluble amyloid fibrils, which deposit extracellularly in tissues such as the heart, nerves, and gastrointestinal tract. This progressive amyloid deposition leads to organ dysfunction, including restrictive cardiomyopathy and neuropathy.  There are two main forms of ATTR amyloidosis: hereditary (variant) and wild-type (senile) ATTR.  Hereditary ATTR (ATTRv) is caused by mutations in the TTR gene. These mutations destabilize the TTR tetramer, making it more prone to dissociation. This increases misfolding and amyloid fibril formation, resulting in systemic amyloid deposition.   Wild-type ATTR (ATTRwt) occurs without genetic mutations and is primarily age-related. Over time, even normal TTR tetramers can become unstable, leading to gradual misfolding and amyloid deposition, particularly in the heart. ATTRwt is a common but often underdiagnosed cause of heart failure with preserved ejection fraction (HFpEF) in elderly individuals.  How does aTTR lead to deleterious effects in the heart and other organ systems?    Transthyretin amyloidosis leads to organ dysfunction through the deposition of misfolded TTR protein as amyloid fib...

The track record of biotechs launched to create curative therapies using CRISPR-Cas9 provides new insights into the old debate over whether platform companies should validate their technology on established targets or pursue new ones. On the latest BioCentury This Week podcast, BioCentury's editors discuss the lessons learned by this small group of companies since their launch a decade ago. They also discuss the entrance of AbbVie into the obesity race via a $350 million deal with Gubra for a clinical stage amylin agonist — does it signal AbbVie's belief in amylin monotherapy, or will the company be hunting for more obesity assets? The editors also talk about recommendations to streamline the early-stage development of rare disease therapies in the U.S.View full story: https://www.biocentury.com/article/65521400:00 - Introduction00:36 - CRISPR Companies09:22 - AbbVie Enters Obesity Race17:19 - Rare Disease Drug ChallengesTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

‘Masterclass' a cargo del científico del Centro Nacional de Biotecnología (CBN) y divulgador Lluis Montoliu sobre la investigación y el diagnóstico de enfermedades raras. Además, y para empezar, Montoliu explica cómo científicos japoneses han logrado eliminar con técnicas CRISPR-Cas9 la tercera copia del ‘Cromosoma 21', que provoca el síndrome de Down. De momento, lo han conseguido in-vitro. 

‘Masterclass' a cargo del científico del Centro Nacional de Biotecnología (CBN) y divulgador Lluis Montoliu sobre la investigación y el diagnóstico de enfermedades raras. Además, y para empezar, Montoliu explica cómo científicos japoneses han logrado eliminar con técnicas CRISPR-Cas9 la tercera copia del ‘Cromosoma 21', que provoca el síndrome de Down. De momento, lo han conseguido in-vitro. 

À l'heure de l'intelligence artificielle, le transhumanisme, qui prône l'usage des sciences afin d'améliorer la condition humaine par l'augmentation de ses capacités physiques et mentales, se développe dans l'ombre. En 2012, les chercheuses Emmanuelle Charpentier et Jennifer Doudna, prix Nobel de chimie 2020, ont créé un système de modification du génome humain, rapide et peu coûteux. Leur technique, appelée CRISPR-Cas9, a été créée dans le but d'aider à lutter contre les maladies génétiques. Mais derrière la prouesse d'une telle technologie se sont des questions éthiques reviennent. En effet, les questionnement autour l'idéologie eugéniste reviennent sur de la scène, il s'agit de la sélection du patrimoine génétique des générations futures d'une population en fonction d'un cadre de choisi.  D'où vient l'eugénisme ? Pourquoi parle-t-on d'eugénisme positif ? Pourquoi ce concept est-il d'actualité ? Écoutez la suite de cet épisode de "Maintenant vous savez". Un podcast Bababam Originals, écrit et réalisé par Samuel Lumbroso. À écouter aussi : Qu'est-ce que le racisme environnemental ? Quel est ce mouvement qui fait participer les amateurs à la science ? Que risque-t-on à devenir volontaire pour la science ? Retrouvez tous les épisodes de "Maintenant vous savez". Première diffusion le 14/07/23 Learn more about your ad choices. Visit megaphone.fm/adchoices

Sorti en 1997 et réalisé par Andrew Niccol, "Bienvenue à Gattaca" (Gattaca en version originale) est considéré par la NASA comme le film de science-fiction le plus réaliste de tous les temps. Cette distinction repose sur la plausibilité scientifique du scénario, qui aborde un futur où le génie génétique joue un rôle central dans la société humaine. Contrairement à d'autres films de science-fiction centrés sur des technologies lointaines ou futuristes, "Bienvenue à Gattaca" explore des avancées qui pourraient devenir réalité dans un avenir proche.L'intrigue du film se déroule dans un monde où les enfants sont conçus en laboratoire, permettant aux parents de choisir les caractéristiques génétiques idéales pour garantir la santé, l'intelligence et les aptitudes physiques optimales. Ceux qui naissent de manière naturelle, sans intervention génétique, sont désavantagés et subissent une discrimination institutionnalisée. Le personnage principal, Vincent Freeman, est un "invalide", c'est-à-dire un individu né sans sélection génétique, qui rêve d'intégrer Gattaca, une prestigieuse institution spatiale. Pour contourner les barrières génétiques, il usurpe l'identité d'un individu génétiquement "supérieur", soulevant ainsi des questions éthiques fondamentales sur le déterminisme génétique et le libre arbitre.Ce que la NASA a particulièrement apprécié dans "Bienvenue à Gattaca", c'est son approche réaliste des avancées en biotechnologie et en eugénisme. Avec les progrès actuels dans la manipulation du génome humain, comme la technologie CRISPR-Cas9, il est désormais envisageable de modifier l'ADN pour prévenir certaines maladies héréditaires et optimiser les caractéristiques humaines. Le film soulève des préoccupations sur l'émergence potentielle d'une société divisée entre "génétiquement privilégiés" et "naturels", ce qui résonne fortement avec les débats bioéthiques actuels.En plus de son réalisme scientifique, le film se distingue par son atmosphère épurée et son style rétro-futuriste, mettant en avant une vision dystopique où les progrès scientifiques conduisent à de nouvelles formes de discrimination. L'absence de technologies extravagantes renforce l'impression que ce futur est à portée de main, rendant le récit d'autant plus crédible.En conclusion, "Bienvenue à Gattaca" offre une réflexion percutante sur les dérives possibles du génie génétique, en s'appuyant sur des fondements scientifiques solides. Sa reconnaissance par la NASA témoigne de la pertinence de ses questionnements et de sa capacité à anticiper les défis éthiques et sociaux liés aux avancées biotechnologiques modernes. Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

Join CardioNerds Heart Failure Section Chair Dr. Jenna Skowronski, episode lead Dr. Apoorva Gangavelli, and expert faculty Dr. Ronald Witteles as they discuss the Nex-Z trial. This was a phase 1, open-label trial investigating nex-z, a CRISPR-Cas9-based treatment, in 36 patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM). The primary objectives were aimed at studying the safety and pharmacodynamics of this novel gene-based treatment modality. This episode dives into the nuances of the data, future directions for investigation, and future clinical implications. CardioNerds Journal Club PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! References - The Nex-Z Trial Fontana, M., Solomon, S. D., Kachadourian, J., Walsh, L., Rocha, R., Lebwohl, D., Smith, D., Täubel, J., Gane, E. J., Pilebro, B., Adams, D., Razvi, Y., Olbertz, J., Haagensen, A., Zhu, P., Xu, Y., Leung, A., Sonderfan, A., Gutstein, D. E., & Gillmore, J. D. (2024). CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran for ATTR Cardiomyopathy. The New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2412309

2025 promises to be another busy year for intellectual property law. In this episode of IP Talk with Wolf Greenfield, you'll hear Wolf Greenfield attorneys from a variety of practice areas reviewing some of the top issues of 2024 and offering their insights on what to expect in the months ahead. Here are some of the highlights:01:02 - Chelsea Loughran's thoughts on The University of California v. Broad Institute, a federal court case involving competing patent applications for the CRISPR-Cas9 gene-editing system02:25 - Zach Piccolomini is watching the Unified Patent Court (UPC) for upcoming decisions in the standard essential patent space and “fair, reasonable and non-discriminatory” royalties03:34 - Jonathan Roses with insight on recent Orange Book developments and what to expect with the new administration  05:31 - Jen Wang offers advice for dealing with rejections in the wake of the Federal Circuit overturning a 40-year-old obviousness test for design patents in the LKQ v. GM case06:34 - Scott McKeown on noteworthy 2024 developments at the USPTO and some thoughts for what might happen in 2025 08:43 - John Strand on the Dewberry case, which was just argued before the Supreme Court (a decision is expected in the spring)10:23 - Gabe McCool discusses the BIO Secure Act  

Emmanuelle Charpentier has received the Nobel Prize in Chemistry for discovering genetic scissors –– CRISPR/Cas9. She was the head of the jury of the ESET Science Award and gave a lecture for students during the ESET4Schools event. So did Samuel, so they have got some time to discuss a little. Has the name CRISPR/Cas9 stuck or can we change it to something simpler? Will gene modifications change humankind in the next century? How to become a good scientist? This and much more have been asked by Samuel. Na Youtube nájdete epizódu s (automatickými) titulkami.  Máme novú knihu – Rozhovory o vesmíre https://www.martinus.sk/2901887-rozhovory-o-vesmire/kniha Podcastové hrnčeky a ponožky nájdete na stránke https://vedator.space/vedastore/ Vedátora môžete podporiť cez stránku Patreon https://www.patreon.com/Vedator_sk   Všetko ostatné nájdete tu https://linktr.ee/vedatorsk Vedátorský newsletter http://eepurl.com/gIm1y5

Imaginez pouvoir utiliser l'ADN, le support fondamental de l'information génétique de tous les êtres vivants, pour stocker des données numériques. C'est exactement ce que des scientifiques ont réalisé, et c'est fascinant ! Le 12 juillet 2017, une étude publiée dans Nature a révélé que des chercheurs ont réussi à encoder et stocker un GIF — une série d'images animées — dans l'ADN de Escherichia coli, une bactérie intestinale commune. D'abord, rappelons que l'ADN est un polymère constitué de quatre bases azotées : adénine (A), thymine (T), cytosine (C) et guanine (G). Ces quatre "lettres" forment un code très dense qui peut contenir des quantités massives d'informations. Si l'on pense à l'ADN comme à un langage, les chercheurs ont trouvé un moyen de convertir des données numériques, comme les pixels d'une image ou les images d'un GIF, en ce langage biologique. Pour ce faire, ils ont utilisé la technologie CRISPR-Cas9, connue pour ses capacités d'édition génomique de haute précision. CRISPR agit comme des "ciseaux moléculaires" capables d'insérer des séquences d'ADN de manière spécifique dans le génome d'une cellule. Dans cette expérience, les scientifiques ont traduit chaque pixel du GIF en une séquence de bases A, T, C, et G, qu'ils ont ensuite insérée dans l'ADN de la bactérie. CRISPR a permis d'encoder ces données image par image, de manière séquentielle, dans le génome des cellules de E. coli. Le GIF choisi pour cette expérience était un extrait historique d'une série d'images d'un cheval au galop, créé par Eadweard Muybridge, une référence aux débuts du cinéma. Une fois le GIF encodé dans l'ADN des bactéries, celles-ci se sont reproduites, transmettant ces informations génétiques à leurs descendants. Pour vérifier si le stockage avait fonctionné, les chercheurs ont séquencé l'ADN des bactéries, récupéré les données, et reconstitué l'image animée. Résultat : le GIF a pu être reconstitué, montrant que l'ADN avait fidèlement stocké et protégé ces données. Ce travail est révolutionnaire parce qu'il démontre le potentiel de l'ADN comme support de stockage de données extrêmement dense et stable. Un gramme d'ADN peut théoriquement contenir 215 millions de gigaoctets d'information ! L'ADN ne se dégrade que très lentement dans des conditions favorables, ce qui en fait un moyen prometteur pour l'archivage de données à long terme. Ce type de recherche ouvre des perspectives passionnantes pour l'avenir, où la biologie pourrait s'entremêler avec la technologie de l'information de manière encore plus impressionnante. Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

Did you miss AHA 2024? Listen here to brief discussions of the latest research. Eric Rubin is the Editor-in-Chief of the Journal. Jane Leopold is a Deputy Editor of the Journal. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. E.J. Rubin, J. Leopold, and S. Morrissey. NEJM at AHA — CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran for ATTR Cardiomyopathy. N Engl J Med. DOI: 10.1056/NEJMe2414473.

Alžběta Ressnerová je genová inženýrka, která byla na stáži v prestižní laboratoři Berkeley v Kalifornii. Zde metodou CRISPR-Cas9, také zvanou genetické nůžky, zkoumá, jakým způsobem dopravit opravené buňky na správné místo v těle člověka. Ressnerová si myslí, že takto půjde uzdravit nevyléčitelně nemocné. „V ideálním případě by CRISPR pomáhal zachraňovat životy bez ohledu na sociální postavení,“ doufá vědkyně. Jak se staví k etické otázce upravování genů?

Drive with Dr. Peter Attia: Read the notes at at podcastnotes.org. Don't forget to subscribe for free to our newsletter, the top 10 ideas of the week, every Monday --------- View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter Feng Zhang, a professor of neuroscience at MIT and a pioneering figure in gene editing, joins Peter to discuss his groundbreaking work in CRISPR technology, as well as his early contributions to optogenetics. In this episode, they explore the origins of CRISPR and the revolutionary advancements that have transformed the field of gene editing. Feng delves into the practical applications of CRISPR for treating genetic diseases, the importance of delivery methods, and the current successes and challenges in targeting cells specific tissues such as those in the liver and eye. He also covers the ethical implications of gene editing, including the debate around germline modification, as well as reflections on Feng's personal journey, the impact of mentorship, and the future potential of genetic medicine. We discuss: Feng's background, experience in developing optogenetics, and his shift toward improving gene-editing technologies [2:45]; The discovery of CRISPR in bacterial DNA and the realization that these sequences could be harnessed for gene editing [10:45]; How the CRISPR system fights off viral infections and the role of the Cas9 enzyme and PAM sequence [21:00]; The limitations of earlier gene-editing technologies prior to CRISPR [28:15]; How CRISPR revolutionized the field of gene editing, potential applications, and ongoing challenges [36:45]; CRISPR's potential in treating genetic diseases and the challenges of effective delivery [48:00]; How CRISPR is used to treat sickle cell anemia [53:15]; Gene editing with base editing, the role of AI in protein engineering, and challenges of delivery to the right cells [1:00:15]; How CRISPR is advancing scientific research by fast-tracking the development of transgenic mice [1:06:45]; Advantages of Cas13's ability to direct CRISPR to cleave RNA and the advances and remaining challenges of delivery [1:11:00]; CRISPR-Cas9: therapeutic applications in the liver and the eye [1:19:45]; The ethical implications of gene editing, the debate around germline modification, regulation, and more [1:30:45]; Genetic engineering to enhance human traits: challenges, trade-offs, and ethical concerns [1:40:45]; Feng's early life, the influence of the American education system, and the critical role teachers played in shaping his desire to explore gene-editing technology [1:46:00]; Feng's optimism about the trajectory of science [1:58:15]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube

Drive with Dr. Peter Attia Key Takeaways The human genome was sequenced 25 years ago, what's the delay in editing? We know the sequence of the genes but we don't know what most of the genes do, nor do we fully understand the coding and non-coding sequence (yet)CRISPR is an adaptive immune system: After the first infection, the bacteria has been ‘vaccinated' against the virus The next time the virus comes around, it will inject its genetic information into the bacteria but now the bacteria in the CRISPR area have a signature of the virusDifficulties in application of CRISPR: CRISPR uses a guide RNA to recognize the virus DNA but delivery of the Cas + guide RNA needs to be precise and the protein is too large to insert with ease But, solving the delivery issue doesn't mean CRISPR is suitable for all diseases; its most potent application is for genetic mutations (and likely not cancer which has many different mutations in the cell)Future goals of CRISPR technology: Creating more feasible Cas and guide RNA delivery system; inserting large genes into the genome, precisely and efficientlyEthical considerations of gene editing germline: Slippery slope argument: If we allow X and Y, we will enter an unchartered territory with designer babies, making babies smarter (which we don't know how to do), etc. It's worth noting that athletics, and intelligence, are more complicated than we want to believe; even with the right genetics, environment plays a huge role in realizing genesThinking about how the line should be drawn: Is there an obvious and important medical benefit?Read the full notes @ podcastnotes.org View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter Feng Zhang, a professor of neuroscience at MIT and a pioneering figure in gene editing, joins Peter to discuss his groundbreaking work in CRISPR technology, as well as his early contributions to optogenetics. In this episode, they explore the origins of CRISPR and the revolutionary advancements that have transformed the field of gene editing. Feng delves into the practical applications of CRISPR for treating genetic diseases, the importance of delivery methods, and the current successes and challenges in targeting cells specific tissues such as those in the liver and eye. He also covers the ethical implications of gene editing, including the debate around germline modification, as well as reflections on Feng's personal journey, the impact of mentorship, and the future potential of genetic medicine. We discuss: Feng's background, experience in developing optogenetics, and his shift toward improving gene-editing technologies [2:45]; The discovery of CRISPR in bacterial DNA and the realization that these sequences could be harnessed for gene editing [10:45]; How the CRISPR system fights off viral infections and the role of the Cas9 enzyme and PAM sequence [21:00]; The limitations of earlier gene-editing technologies prior to CRISPR [28:15]; How CRISPR revolutionized the field of gene editing, potential applications, and ongoing challenges [36:45]; CRISPR's potential in treating genetic diseases and the challenges of effective delivery [48:00]; How CRISPR is used to treat sickle cell anemia [53:15]; Gene editing with base editing, the role of AI in protein engineering, and challenges of delivery to the right cells [1:00:15]; How CRISPR is advancing scientific research by fast-tracking the development of transgenic mice [1:06:45]; Advantages of Cas13's ability to direct CRISPR to cleave RNA and the advances and remaining challenges of delivery [1:11:00]; CRISPR-Cas9: therapeutic applications in the liver and the eye [1:19:45]; The ethical implications of gene editing, the debate around germline modification, regulation, and more [1:30:45]; Genetic engineering to enhance human traits: challenges, trade-offs, and ethical concerns [1:40:45]; Feng's early life, the influence of the American education system, and the critical role teachers played in shaping his desire to explore gene-editing technology [1:46:00]; Feng's optimism about the trajectory of science [1:58:15]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter Feng Zhang, a professor of neuroscience at MIT and a pioneering figure in gene editing, joins Peter to discuss his groundbreaking work in CRISPR technology, as well as his early contributions to optogenetics. In this episode, they explore the origins of CRISPR and the revolutionary advancements that have transformed the field of gene editing. Feng delves into the practical applications of CRISPR for treating genetic diseases, the importance of delivery methods, and the current successes and challenges in targeting cells specific tissues such as those in the liver and eye. He also covers the ethical implications of gene editing, including the debate around germline modification, as well as reflections on Feng's personal journey, the impact of mentorship, and the future potential of genetic medicine. We discuss: Feng's background, experience in developing optogenetics, and his shift toward improving gene-editing technologies [2:45]; The discovery of CRISPR in bacterial DNA and the realization that these sequences could be harnessed for gene editing [10:45]; How the CRISPR system fights off viral infections and the role of the Cas9 enzyme and PAM sequence [21:00]; The limitations of earlier gene-editing technologies prior to CRISPR [28:15]; How CRISPR revolutionized the field of gene editing, potential applications, and ongoing challenges [36:45]; CRISPR's potential in treating genetic diseases and the challenges of effective delivery [48:00]; How CRISPR is used to treat sickle cell anemia [53:15]; Gene editing with base editing, the role of AI in protein engineering, and challenges of delivery to the right cells [1:00:15]; How CRISPR is advancing scientific research by fast-tracking the development of transgenic mice [1:06:45]; Advantages of Cas13's ability to direct CRISPR to cleave RNA and the advances and remaining challenges of delivery [1:11:00]; CRISPR-Cas9: therapeutic applications in the liver and the eye [1:19:45]; The ethical implications of gene editing, the debate around germline modification, regulation, and more [1:30:45]; Genetic engineering to enhance human traits: challenges, trade-offs, and ethical concerns [1:40:45]; Feng's early life, the influence of the American education system, and the critical role teachers played in shaping his desire to explore gene-editing technology [1:46:00]; Feng's optimism about the trajectory of science [1:58:15]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube

Ficha técnica Hosts: Leticia Dáquer e Thiago Corrêa  Edição: Leticia Dáquer Capa: Leticia Dáquer Data da gravação: 20/10/2024 Data da publicação: 24/10/2024   Músicas/áudios: The Oldest Song in the World The Most Mysterious Song on the Internet - HQ Stereo Remastered   Coisas mencionadas no episódio: Episódio do Stuff You Should Know sobre mistérios da internet, incluindo a música desconhecida Música da bunda do Bosch A música mais misteriosa da internet (Wikipedia) But what is CRISPR-Cas9? An animated introduction to Gene Editing   Bom Leticia World-first therapy using donor cells sends autoimmune diseases into remission (Nature, 04/10/2024) Discovering Roman mosaics - A fabulous new find where history meets luxury in Antakya (World Archeology, 18/11/2020) Thiago Ouça a música mais antiga do mundo, de 3.400 anos (Olhar Digital, 29/07/2024) World's first ‘meltdown-proof' nuclear reactor aces safety test (New Atlas, 24/07/2024) Brazilian artist swaps historical coin in British Museum for a fake (The Guardian, 22/07/2024)   Mau Leticia Políticos de cidade alemã querem restringir venda de kebab (Carta Capital, 12/08/2024) Thiago  Music industry's 1990s hard drives, like all HDDs, are dying (12/09/2024)   Feio Leticia State-of-the-Art Fire Station Leveled by Blaze (Newsweek, 18/10/2024) Woman passes her driving test on her 960th go after spending £11,000 (The Mirror, 26/03/2023) Comandante de navio dos EUA é rebaixado após atirar com a mira ao contrário (UOL, 04/09/2024) Engenheira mantém 7,4 mil abas abertas no Firefox há mais de dois anos (Terra, 07/05/2024) Two San Francisco nudists save man from being attacked in street by a "crazy kind of pirate guy"with a blowtorch (MSN, 07/2024) Thiago Alemanha vai parar de usar disquetes em navios de guerra (Tecnoblog, 07/2024) MS-DOS and Windows 3.11 still run train dashboards at German railway — company listed admin job for 30-year-old operating system (Tom's Hardware, 29/01/2024) Math student builds fusion reactor at home with help from Claude AI and $2,000 (Techspot, 03/09/2024) Restaurant sues customer over $3,000 waitress tip he left on $13 meal (Unilad, 01/07/2024) Maldives minister arrested for performing ‘black magic' on President Muizzu: Report (Hindustan Times, 28/06/2024)   Parceria com Veste Esquerda: Agora tem camiseta do Pistolando direto no site da Veste Esquerda! Mas o código de desconto PISTOLA10 dá 10% de desconto na sua compra da nossa e de outras camisetas maneiríssimas esquerdopatas!   Parceria com Editora Boitempo: compre livros por esse link aqui pra gente ganhar uns trocados de comissão :)   Nosso link de associados da Amazon, mas só em último caso, hein: bit.ly/Pistolando    Parceria com o ICL: inscreva-se nos cursos pelo nosso link   Esse podcast é produzido pelo Estopim Podcasts. Precisa de ajuda pra fazer o seu podcast? Chega mais, que a gente te dá uma mãozinha.     Links do Pistolando www.pistolando.com contato@pistolando.com Twitter: @PistolandoPod Instagram: @PistolandoPod   Apóie o Pistolando no Catarse, no Patreon e agora também no PicPay, ou faça um Pix pra gente usando a chave contato@pistolando.com   Descrição da capa:  

durée : 00:05:28 - Avec sciences - par : Alexandra Delbot - La xénotransplantation est une technique de greffe d'organes provenant d'animaux. Grâce à l'avènement des ciseaux moléculaires CRISPR-Cas9, les risques de rejet suraigu sont considérablement réduits. Où en est la recherche actuellement ? Quels sont les enjeux éthiques de la xénogreffe ?

As the global population approaches 10 billion by 2050, the challenge of providing safe, nutritious food is growing more urgent. Climate change is further straining food systems, impacting water availability, crop yields, and livestock health. In this episode, two experts discuss innovative biotech solutions aimed at addressing these pressing issues, offering hope for a sustainable path forward in feeding the world.Follow us on LinkedIn, X, Facebook and Instagram. Visit us at https://www.bio.org/

Comenzamos la segunda hora de Poniendo las Calles y lo hacemos con una historia muy inspiradora. Y también hablamos de genética y de lo que esconde tanto la medicina personalizada como lo que nos permite hacer la Tecnología CRISPR-Cas9 de la mano de Sergio Parra, el coordinador de Genoma.

Den ärftlig Skelleftesjukan gör att internationella forskare riktar sina ögon mot norra Sverige för genterapier. Vissa fungerar bra mot problem i hjärtat. Men utanför EU finns billigare alternativ. Lyssna på alla avsnitt i Sveriges Radio Play. Det är med viss frustration som forskarna i Umeå och Skellefteå är med om spännande ny internationell forskning kring den ärftliga sjukdomen Skelleftesjukan. Den som heter ärftlig transtyretin amyloidos.Skelleftesjukan idealisk för genterapierDen har blivit en modellsjukdom eftersom det bara är en gen som skapar det felveckade proteinet, och det är ett protein som vuxna i hög uträckning kan klara sig utan. Därför är den idealisk för nya behandlingar, bland annat genterapier.Åke testar nya genterapier för hjärtat 83-årige Åke Johansson i Skellefteå har problem med hjärtat. Han har testat nya behandlingar, både tabletter och nu en spruta i magen mot Skelleftesjukan. Sprutan med genterapi är nu under utvärdering. Han känner sig väldigt omhändertagen även om han aldrig i studierna vet om han får aktiv substans eller sockerpiller, placebo.Svenska forskare i forskningsfrontenMånga forskare i Sverige har medverkat i att ta fram olika nya behandlingar. Medverkar i Vetenskapsradion hälsa gör Mona Olofsson, forsknings-biomedicinsk analytiker och medicine doktor i Skellefteå, Kurt Boman, professor emeritus i kardiolog och invärtesmedicin vid Skellefte lasarett, Jonas Wixner, överläkare och chef på amyloidoscentrum och medicincentrum vid Umeå universitetssjukhus, Ole Suhr, senior professor i medicin samt Björn Pilebro/överläkare i kardiologi och huvudansvarig för CRISPR-Cas9 studien för Skelleftesjukan vid Umeå universitetssjukhus.Tidigare program om Skelleftesjukan i Vetenskapsradion Hälsa heter ”Genkniven hjälper Eva-Britt i kampen mot Skelleftesjukan”. Det sändes 29 feb i år.Det här programmet sändes första gången 7 mars i år. Programledare och producent Annika Östman annika.ostman@sverigesradio.se

Eva-Britt är en av nio svenskar som behandlats med den nobelprisade genkniven CRISPR/Cas9 mot den ärftliga sjukdomen Skelleftesjukan. En sjukdom som nu lockar många internationella forskare. Lyssna på alla avsnitt i Sveriges Radio Play. Trots att Eva-Britt hade sett effekterna av Skelleftesjukan i sitt jobb som arbetsterapeut så hade hon svårt att få gehör för sina farhågor. Hon började ana att stickningarna i benen kunde innebära att att hon själv hade sjukdomen. Läkarna trodde inte att hon kunde ha den ärftliga sjukdomen.Lång tid att få diagnos för SkelleftesjukaDet tog nästan tre år innan hon fick sin diagnos. Men det smärtade i hennes mamma-hjärta när hon fick beskedet. Så när hon fick möjlighet att vara med i en ny genterapistudie blev hon glad.-Använd min kropp! Det blir jättebra! Försök att hitta botemedel, säger Eva-Britt i Vetenskapsradion Hälsa. Skelleftesjukan modellsjukdom för genterapierOrsaken till att Skelleftesjukan har blivit en modellsjukdom för forskare och läkemedelsföretag när de tar fram nya genterapier är att den är ganska geografiskt avgränsad, och att det är en enda gen som orsakar felveckade proteiner, samt att generna finns i levern - som är lätta att komma åt. Det berättar Eva-Britts läkare Jonas Wixner vid Universitetssjukhus i Umeå.Den som är huvudansvarig för CRISPR/Cas9 studien i Sverige, kardiologen Björn Pilebro, vid Umeå universitets sjukhus konstaterar att norrlänningar har blivit försökskaniner för genterapier, men något som man också kan dra nytta av.Medverkar gör: Eva-Britt i Skellefteå som fick behandling med genkniven CRISPR/Cas9 i december 2022, Björn Pilebro som är huvudansvarig för CRISPR/Cas9 studien mot Skelleftesjukan i Sverige och överläkare på kardiologen vid Umeå universitetssjukhus samt Jonas Wixner, överläkare vid amyloidoscentrum och medicincentrum vid Umeå universitetssjukhus och Eva-Britts läkare..Programmet sändes första gången 29 februari.Programledare och producent Annika Östmanannika.ostman@sverigesradio.se

CRISPR-Cas9 gene editing technology is one of the newest and most promising tools in science. But what is it? How does it work? And what are scientists doing with this technology that has been described as a molecular genetic scalpel? In this first of two episodes, we talk with Dr. Rodolphe Barrangou, the first scientist to discover and publish results demonstrating what the CRISPR-Cas9 system can do, thereby opening the door for other scientists and discoveries.

In this episode, Prof Michael Chapman, discusses the world of gene editing. He explores the groundbreaking potential of CRISPR Cas9, a tool that could revolutionize the way we address genetic diseases. Prof. Chapman discusses the ethical dilemmas highlighted by controversial experiments, as well as the future implications of these advancements. He also touches on the role of epigenetic testing in IVF treatments and its potential to enhance reproductive success.  Join us for an insightful conversation on the science and ethics of gene editing. Explore the 'Prof. Michael Chapman - The IVF Journey' Facebook Page, your reliable destination for cutting-edge insights and guidance within the realm of In Vitro Fertilization (IVF). Don't miss out on the IVF Journey podcast; stay informed with the latest episode updates. Tune in for expert discussions and valuable information on navigating the intricate path of IVF.

Menschen spekulieren an der Börse. Warum tun sie das? Weil sie schnell reich werden möchten! Ist das etwas Verwerfliches? Nein, das ist es nicht. Allerdings ist die Gefahr Geld zu verlieren relativ hoch. Worauf man daher also achten sollte, welches Potential aber auch die Branchen und die Entwicklungen haben, die wirklich die Welt verändern: Darüber möchte ich heute im Podcast reden.
 ► An diese E-Mail-Adresse kannst du mir deine Themen-Wünsche senden: podcast@lars-erichsen.de
 ► Den neuen Podcast “Buy The Dip” findet ihr hier: https://buythedip.podigee.io
 ► Schau Dir hier die neue Aktion der Rendite-Spezialisten an: https://www.rendite-spezialisten.de/aktion
 ► TIPP: Sichere Dir wöchentlich meine Tipps zu Gold, Aktien, ETFs & Co. – 100% gratis: https://erichsen-report.de/
 Viel Freude beim Anhören. Über eine Bewertung und einen Kommentar freue ich mich sehr. Jede Bewertung ist wichtig. Denn sie hilft dabei, den Podcast bekannter zu machen. Damit noch mehr Menschen verstehen, wie sie ihr Geld mit Rendite anlegen können.
 ► Mein YouTube-Kanal: http://youtube.com/ErichsenGeld
 ► Folge meinem LinkedIn-Account: https://www.linkedin.com/in/erichsenlars/
 ► Folge mir bei Facebook: https://www.facebook.com/ErichsenGeld/
 ► Folge meinem Instagram-Account: https://www.instagram.com/erichsenlars
 Quelle der Audio-Snippets, abgerufen am 17.07.2024:
 URL: https://www.youtube.com/watch?v=cO-2NAl7Sm0 Titel: One more thing ... YouTube-Kanal: All About Steve Jobs
 URL: https://www.youtube.com/watch?v=ZwiKaz0kr24 Titel: Projekt U-Bahn 100 startet Testphase YouTube-Kanal: Hamburg 1 Fernsehen
 URL: https://www.youtube.com/watch?v=ouXrsr7U8WI Titel: Gen-editing mit CRISPR/Cas9 (english subtitles) YouTube-Kanal: MaxPlanckSociety
 URL: https://www.youtube.com/watch?v=kPd56OY2ED8 Titel: Richard Branson Speaks on Plan for Space Tourism YouTube-Kanal: Smithsonian Channel
 Die verwendete Musik wurde unter www.soundtaxi.net lizenziert. 
 Sound-Effekte stammten von: applause.wav by thedapperdan -- https://freesound.org/s/26807/ -- License: Creative Commons 0
 
Ein wichtiger abschließender Hinweis: Aus rechtlichen Gründen darf ich keine individuelle Einzelberatung geben. Meine geäußerte Meinung stellt keinerlei Aufforderung zum Handeln dar. Sie ist keine Aufforderung zum Kauf oder Verkauf von Wertpapieren.
 Offenlegung wegen möglicher Interessenkonflikte: Die Autoren sind in den folgenden besprochenen Wertpapieren bzw. Basiswerten zum Zeitpunkt der Veröffentlichung investiert: -

In this episode, Buck discusses gene editing and its potential implications for human health and longevity. He explains the basics of gene editing, including the structure of DNA and how genes are transcribed into proteins, then dives into the history and development of gene editing techniques, focusing on the game-changing CRISPR-Cas9 technology. He also explores the practical applications of gene editing, such as its use in treating sickle cell anemia and other genetic diseases, as well as the potential for human longevity, including targeting genes associated with aging and reversing epigenetic age.

För 50 år sen lärde sig forskare att flytta gener mellan olika organismer. Då visste ingen vart gentekniken skulle leda. Idag växer GMO-grödor på många åkrar - medan frågetecken kvarstår i medicinen. Lyssna på alla avsnitt i Sveriges Radio Play. De första försöken med att förse bakterier med nya gener som kom från virus gjordes i början av 1970-talet. Farhågor uppstod snart kring riskerna. Skulle de nya transgena bakterierna kunna leda till en smittsam form av cancer, eller andra nya okända biologiska faror?Frågan gjorde att forskarna frivilligt gjorde en paus för att reda ut hur farlig den nya gentekniken var.Arbetet med de nya gentekniska verktygen kom snart igång igen, men nu omgärdade av en rad strikta säkerhetsåtgärder som många gånger gäller än idag, för att genförändrade växter eller bakterier inte okontrollerat ska slippa ut i omgivningen.När gensaxen Crispr/Cas9 presenterades 2012 kom nya möjligheter, och diskussionen tog fart igen – inte minst om vad man ska få göra med mänskliga gener som går i arv.I programmet medverkar genetikerna Magnus Lundgren, Uppsala universitet och Juha Kere från Karolinska Institutet, samt Niklas Juth som är professor i medicinsk etik i Uppsala.Programmet är en repris från februari 2024. Programledare: Tomas LindbladProducent: Camilla Widebeckcamilla.widebeck@sverigesradio.se

We love to hear from our listeners. Send us a message.KSQ Therapeutics' CSO, Micah Benson, Ph.D., joins Erin Harris to discuss how Tumor-Infiltrating Lymphocytes (TILs) as a treatment modality have the potential to treat a variety of solid tumor types. Benson explains KSQ's Phase 1/2 clinical study, KSQ-001EX, which consists of TILs in which the SOCS1 gene is inactivated by CRISPR/Cas9 gene editing. In addition to solid tumors, Benson also addresses the therapeutic potential for autoimmune disease.

La puntata si apre parlando di RNA, dopo una panoramica sulle funzioni di RNA messaggero, RNA di trasporto e RNA ribosomale, parliamo di quegli RNA meno conosciuti ma che stiamo capendo solo ora possono avere ruoli fondamentali. E uno di questi RNA è stato appena scoperto e denominato "bridge RNA" e con il suo enzima sembra avere una funzione simile a quella di CRISPR-Cas9 fornendoci un nuovo strumento di editing genetico.Anna intervista Giovanni Di Liberto, Professore di Sistemi Intelligenti al Trinity College a Dublino che ci parla di neuroscienze della musica. In particolare, Giovanni descrive come viene elaborato il suono nella corteccia cerebrale, quali sono le caratteristiche di un suono che lo fanno percepire come musicale e quanto contribuiscono la nostra esperienza e la nostra cultura a influenzare la percezione della musica.Tornati in studio dopo una barza radioattiva Andre ci parla del suo sogno nel cassetto per la pensione, non semplicemente guardare i cantieri, ma guardare il cantiere dell'acceleratore di muoni. Quali sono le sfide tecnologiche? E perchè accelerare muoni?Diventa un supporter di questo podcast: https://www.spreaker.com/podcast/scientificast--1762253/support.

Welcome to the inaugural episode of the Two Bears Podcast! In this episode of "Two Bears Podcast," Chef Zev Bennett & Chef Don Splain discuss their culinary journeys and experiences. Chef Don shares some of his Native American heritage and early cooking memories. Chef Zev Bennett recounts his childhood fascination with cookbooks while growing up in an Orthodox Jewish household. They explore their paths into the culinary world, including pivotal moments like Chef Zev's change in education tract from studying CRISPR-Cas9 to culinary school in Thailand. The conversation touches on the influence of culinary legends like Escoffier and the impact of African American culture on American cuisine.

TAKEAWAYSPeople who take the mark of the beast during the End Times will likely be genetically altered in some wayHuman depopulation is the top goal of the global elites who are working for LuciferAt some point, the military powers of the world will answer to the Antichrist, whom Scott believes will be a NephilimGod's wrath is coming for those who have broken his everlasting covenant with mankind

TWiV reviews viruses in the news: Chinese scientist who released the SARS-CoV-2 genome sequence sleeps in the street, a case of measles in Haifa, spread of waterborne infectious diseases in Gaza, interstate spread of avian influenza A(H5N1) in dairy cattle, and an orangutan heals himself with medicinal plants, followed by identification of a cell receptor for parechoviruses, and blockade of necroptosis prevents lung injury in severe influenza. Hosts: Vincent Racaniello, Dickson Despommier, and Alan Dove Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode MicrobeTV Discord Server MicrobeTV store at Cafepress Become a member of ASV (asv.org) The New City by Dickson Despommier (blog post) International Conference on Pandemic Preparedness Chinese virologist sleeps on street (Nature) Measles in Haifa (Jerusalem Post) Waterborne illness spreads in Gaza (Reuters) Interstate spread of H5N1 virus in dairy cattle (bioRxiv) Orangutan uses medicinal plants (Science) Parechovirus cell receptor identified (Nat Comm) Necroptosis blockade prevents lung injury in influenza (Nature) Necroptosis, pyroptosis and apoptosis (Cell Mol Immunol) Letters read on TWiV 1111 Timestamps by Jolene. Thanks! Weekly Picks Dickson – NASA's Webb Finds Ethanol, Other Icy Ingredients for Worlds Alan – MyClimate.org calculators Vincent – Twenty-Five Lectures in Virology 2024 Listener Picks Alan – NPR story and interactive quiz on pandemic respiratory disease transmission Az – H5N1 Avian Flu in Mammals Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv

Alô, Alô! Se você pudesse escolher ter nascido diferente, você escolheria? Por exemplo, se soubesse que você poderia nascer com uma doença grave, você escolheria mudar isso? Ou mudar o seu tamanho, a sua cor de pele, sua memória... Você arriscaria fazer isso? E se você pudesse usar esse poder em outros seres vivos? Ou seja, escolher as características de animais, micróbios e plantas antes mesmo de eles nascerem? Por exemplo, escolher que uma vaca nasça sem chifre; ou que uma bactéria seja capaz de produzir um medicamento; ou que uma planta tenha mais nutrientes e frutos maiores? Estou falando de exemplos do poder que a edição genética pode ter. Muitas das coisas já são possíveis de serem feitas. Existem algumas maneiras de se fazer essa edição genética. Uma das mais famosas é a transgenia (que produz os alimentos transgênicos), mas uma nova maneira de fazer edição genética é o método CRISPR. Esse episódio está muito especial! Em um forma de ensaio jornalístico e com uma narrativa envolvente, conversamos com seis especialistas para entender o que é edição genética, quais as vantagens e perigos de usá-los e como eles são vistos pela legislação brasileira. Aperta o play e entenda essa história. Assuntos abordados: 00:00 - O que é edição genética? DNA, genoma e fenótipo.04:05 - O que é CRISPR?07:30 - Vantagens de se usar o CRISPR.10:30 - Transgênicos são seguros?17:26 - Problemas do CRISPR: O Efeito Fora do Alvo (off-target).27:39 - Problemas sociais e econômicos que o CRISPR pode causar.37:22 - Efeitos do CRISPR em cadeias alimentares.38:29 - Leis que controlam o CRISPR no Brasil. Especialistas entrevistados: Santuza Teixeira - Professora do Depto. Bioquímica e Imunologia da UFMG. Sarah Agapito - Geneticista do Genok, centro de Biossegurança da Universidade Ártica da Noruega. Gabriel Fernandes - Engenheiro agrônomo e assessor técnico do Centro de Tecnologias Alternativas da Zona da Mata. Renato Cardoso - Professor do programa de pós-graduação em Direito e em Neurociência da UFMG. Leonardo Melgarejo - engenheiro agrônomo que já foi representante do Ministério do Desenvolvimento Agrário na CTNBio. Francisco Aragão - engenheiro agrônomo da Embrapa e doutor em Ciências Biológicas (UnB). Criador do feijão transgênico.

durée : 00:03:34 - Un monde connecté - par : François Saltiel - Utiliser la manipulation génétique pour contrer les menaces écologiques, c'est l'objectif de certains chercheurs qui proposent d'utiliser l'outil de modification du génome CRISPR-Cas9. Cependant, ces avancées soulèvent des préoccupations éthiques et environnementales.

Professor Doudna was awarded the 2020 Nobel Prize in Chemistry with Professor Emmanuelle Charpentier for their pioneering work in CRISPR genome editing. The first genome editing therapy (Casgevy) was just FDA approved, only a decade after the CRISPR-Cas9 editing system discovery. But It's just the beginning of a much bigger impact story for medicine and life science.Ground Truths podcasts are now on Apple and Spotify. And if you prefer videos, they are posted on YouTubeTranscript with links to audio and relevant external linksEric Topol (00:06):This is Eric Topol with Ground Truths, and I'm really excited today to have with me Professor Jennifer Doudna, who heads up the Innovative Genomics Institute (IGI) at UC Berkeley, along with other academic appointments, and as everybody knows, was the Nobel laureate for her extraordinary discovery efforts with CRISPR genome editing. So welcome, Jennifer.Jennifer Doudna (00:31):Hello, Eric. Great to be here.Eric Topol (00:34):Well, you know we hadn't met before, but I felt like I know you so well because this is one of my favorite books, The Code Breaker. And Walter Isaacson did such a wonderful job to tell your story. What did you think of the book?My interview with Walter Isaacson on The Code Breaker, a book I highly recommendJennifer Doudna (00:48):I thought Walter did a great job. He's a good storyteller, and as you know from probably from reading it or maybe talking to others about it, he wrote a page turner. He actually really dug into the science and all the different aspects of it that I think created a great tale.Eric Topol (01:07):Yeah, I recommended highly. It was my favorite book when it came out a couple years ago, and it is a page turner. In fact, I just want to read one, there's so many quotes out of it, but in the early part of the book, he says, “the invention of CRISPR and the plague of Covid will hasten our transition to the third great revolution of modern times. These revolutions arose from the discovery beginning just over a century ago, of the three fundamental kernels of our existence, the atom, the bit, and the gene.” That kind of tells a big story just in one sentence, but I thought I'd start with the IGI, the institute that you have set up at Berkeley and what its overall goals are.Jennifer Doudna (01:58):Right. Well, let's just go back a few years maybe to the origins of this institute and my thinking around it, because in the early days of CRISPR, it was clear that we were really at a moment that was quite unique in the sense that there was a transformative technology. It was going to intersect with lots of other discoveries and technologies. And I work at a public institution and my question to myself was, how can I make sure that this powerful tool is first of all used responsibly and secondly, that it's used in a way that benefits as many people as possible, and it's a tall order, but clearly we needed to have some kind of a structure that would allow people to work together towards those goals. And that was really the mission behind the IGI, which was started as a partnership between UC Berkeley and UCSF and now actually includes UC Davis as well.The First FDA Approved Genome EditingEric Topol (02:57):I didn't realize that. That's terrific. Well, this is a pretty big time because 10 years or so, I guess starting to be 11 when you got this thing going, now we're starting to see, well, hundreds of patients have been treated and in December the FDA approved the first CRISPR therapy for sickle cell disease, Casgevy. Is that the way you say it?Jennifer Doudna (03:23):Casgevy, yeah.Eric Topol (03:24):That must have felt pretty good to see if you go from the molecules to the bench all the way now to actually treating diseases and getting approval, which is no easy task.Jennifer Doudna (03:39):Well, Eric, for me, I'm a biochemist and somebody who has always worked on the fundamentals of biology, and so it's really been extraordinary to see the pace at which the CRISPR technology has been adopted, and not just for fundamental research, but also for real applications. And Casgevy is sort of the crowning example of that so far, is that it's really a technology that we can already see how it's being used to, I think it's fair to say, effectively cure a genetic disease for the first time. Really amazing.Genome Editing is Not the Same as Gene TherapyEric Topol (04:17):Yeah. Now I want to get back to that. I know there's going to be refinements about that. And of course, there's beta thalassemia, so we've got two already, and our mutual friend Fyodor Urnov would say two down 5,000 to go. But I think before I get to the actual repair of the sickle cell defect molecular defect, I think one of the questions I think that people listeners may not know is the differentiation of genome editing with gene therapy. I mean, as you know, there was recently a gene therapy approval for something like $4.25 million for metachromatic leukodystrophy. So maybe you could give us kind of skinny on how these two fundamental therapies are different.Jennifer Doudna (05:07):Right. Well, it's a great question because the terminology sounds kind of the same, and so it could be confusing. Gene therapy goes back decades, I can remember gene therapy being discussed as an exciting new at the time, direction back when I was a graduate student. That was little while ago. And it refers to the idea that we can use a genetic approach for disease treatment or even for a cure. However, it fundamentally requires some mechanism of integrating new information into a genome. And traditionally that's been done using viruses, which are great at doing that. It's just that they do it wherever they want to do it, not necessarily where we want that information to go. And this is where CRISPR comes in. It's a technology allows precision in that kind of genetic manipulation. So it allows the scientist or the clinician to decide where to make a genetic change. And that gives us tremendous opportunity to do things with a kind of accuracy that hasn't been possible before.Eric Topol (06:12):Yeah, no question. That's just a footnote. My thesis in college at University of Virginia, 1975, I'm an old dog, was prospects for gene therapy in man. So it took a while, didn't it? But it's a lot better now with what you've been working on, you and your colleagues now and for the last decade for sure. Now, what I was really surprised about is it's not just of course, these hemoglobin disorders, but now already in phase two trials, you've got hereditary angioedema, which is a life-threatening condition, amyloidosis, cancer ex vivo, and also chronic urinary tract infections. And of course, there's six more others like autoimmune diseases like lupus and type 1 diabetes. So this is really blossoming. It's really extraordinary.Eric Topol (07:11):I mean, wow. So one of the questions I had about phages, because this is kind of going back to this original work and discovery, antimicrobial resistance is really a big problem and it's a global health crisis, and there's only two routes there coming up with new drugs, which has been slow and not really supported by the life science industry. And the other promising area is with phages. And I wonder, since this is an area you know so well, why haven't we put more, we're starting to see more trials in phages. Why haven't we doubled down or tripled down on this to help the antimicrobial resistance problem?Jennifer Doudna (08:00):Well, it's a really interesting area, and as you said, it's kind of one of those areas of science where I think there was interest a while ago and some effort was made for reasons that are not entirely clear to me, at least it fizzled out as a real focused field for a long time. But then more recently, people have realized that there's an opportunity here to take advantage of some natural biology in which viruses can infect and destroy microbes. Why aren't we taking better advantage of that for our own health purposes? So I personally am very excited about this area. I think there's a lot of fundamental work still to be done, but I think there's a tremendous opportunity there as well.CRISPR 2.0Eric Topol (08:48):Yeah, I sure think we need to invest in that. Now, getting back to this sickle cell story, which is so extraordinary. This is kind of a workaround plan of getting fetal hemoglobin built up, but what about actually repairing, getting to fixing the lesion, if you will?Eric Topol (09:11):Yeah. Is that needed?Jennifer Doudna (09:13):Well, maybe it's worth saying a little bit about how Casgevy works, and you alluded to this. It's not a direct cure. It's a mechanism that allows activation of a second protein called fetal hemoglobin that can suppress the effect of the sickle cell mutation. And it's great, and I think for patients, it offers a really interesting opportunity with their disease that hasn't been available in the past, but at the same time, it's not a true cure. And so the question is could we use a CRISPR type technology to actually make a correction to the genetic defect that directly causes the disease? And I think the answer is yes. The field isn't there quite yet. It's still relatively difficult to control the exact way that DNA editing is occurring, especially if we're doing it in vivo in the body. But boy, many people are working on this, as you probably know. And I really think that's on the horizon.Eric Topol (10:19):Yeah. Well, I think we want to get into the in vivo story as well because that, I think right now it's so complicated for a person to have to go through the procedure to get ultimately this treatment currently for sickle cell, whereas if you could do this in vivo and you could actually get the cure, that would be of the objective. Now, you published just earlier this month in PNAS a wonderful paper about the EDVs and the lipid nanoparticles that are ways that we could get to a better precision editing. These EDVs I guess if I have it right, enveloped virus-like particles. It could be different types, it could be extracellular vesicles or whatnot. But do you think that's going to be important? Because right now we're limited for delivery, we're limited to achieve the right kind of editing to do this highly precise. Is that a big step for the future?Jennifer Doudna (11:27):Really big. I think that's gating at the moment. Right now, as you mentioned, somebody that might want to get the drug Casgevy for sickle cell disease or thalassemia, they have to go through a bone marrow transplant to get it. And that means that it's very expensive. It's time consuming. It's obviously not pleasant to have to go through that. And so that automatically means that right now that therapy is quite restricted in the patients that it can benefit. But we imagine a day when you could get this type of therapy into the body with a one-time injection. Maybe someday it's a pill that could be taken where the gene editors target the right cells in the body. In diseases like that, it would be the stem cells in the bone marrow and carry out gene editing that can have a therapeutic benefit. And again, it's one of those ideas that sounds like science fiction, and yet already there's tremendous advance in that direction. And I think over the next, I don't know, I'm guessing 5 to 10 years we're going to see that coming online.Editing RNA, the Epigenome, and the MicrobiomeEric Topol (12:35):Yeah, I'm guessing just because there's so much work on the lipid nanoparticles to tweak them. And there's four different components that could easily be made so much better. And then all these virus-like proteins, I mean, it may happen even sooner. And it's really exciting. And I love that diagram in that paper. You have basically every organ of the body that isn't accessible now, potentially that would become accessible. And that's exciting because whatever blossoming we're seeing right now with these phase two trials ongoing, then you basically have no limits. And that I think is really important. So in vivo editing big. Now, the other thing that's cropped up in recent times is we've just been focused on DNA, but now there's RNA editing, there's epigenetic or epigenomic editing. What are your thoughts about that?Jennifer Doudna (13:26):Very exciting as well. It's kind of a parallel strategy. The idea there would be to, rather than making a permanent change in the DNA of a cell, you could change just the genetic output of the cell and or even make a change to DNA that would alter its ability to be expressed and to produce proteins in the cell. So these are strategies that are accessible, again, using CRISPR tools. And the question is now how to use them in ways that will be therapeutically beneficial. Again, topics that are under very active investigation in both academic labs and at companies.Eric Topol (14:13):Yeah. Now speaking of that, this whole idea of rejuvenation, this is Altos. You may I'm sure know my friend here, Juan Carlos Belmonte, who's been pushing on this for some time at Altos now formerly at Salk. And I know you helped advise Altos, but this idea of basically epigenetic, well using the four Yamanaka factors and basically getting cells that go to a state that are rejuvenated and all these animal models that show that it really happens, are you thinking that really could become a therapy in the times ahead in patients for aging or particular ideas that you have of how to use that?Jennifer Doudna (15:02):Well, you mentioned the company Altos. I mean, Altos and a number of other groups are actively investigating this. Not I would say specifically regarding genome editing, although being able to monitor and probably change gene functions that might affect the aging process could be attractive in the future. I think the hard question there is which genes do we tweak and how do we make sure that it's safe? And better than me I mean, that's a very difficult thing to study clinically because it takes time for one thing, and we probably don't have the best models either. So I think there are challenges there for sure. But along the way, I feel very excited about the kind of fundamental knowledge that will come from those studies. And in particular, this question of how tissues rejuvenate I think is absolutely fascinating. And some organisms do this better than others. And so, understanding how that works in organisms that are able to say regrow a limb, I think can be very interesting.Eric Topol (16:10):And that gets me to that recent study. Well, as you well know, there's a company Verve that's working on the familial hypercholesterolemia and using editing with the PCSK9 through the liver and having some initial, at least a dozen patients have been treated. But then this epigenetic study of editing in mice for PCSK9 also showed results. Of course, that's much further behind actually treating patients with base editing. But it's really intriguing that you can do some of these things without having to go through DNA isn't it?Jennifer Doudna (16:51):Amazing, right? Yeah, it's very interesting.Reducing the Cost of Genome EditingEric Topol (16:54):Wild. Now, one of the things of course that people bring up is, well, this is so darn expensive and it's great. It's a science triumph, but then who can get these treatments? And recently in January, you announced a Danaher-IGI Beacon, and maybe you can tell us a bit about that, because again, here's a chance to really markedly reduce the cost, right?Jennifer Doudna (17:25):That's right. That's the vision there. And huge kudos to my colleague Fyodor Urnov, who really spearheaded that effort and leads the team on the IGI side. But the vision there was to partner with a company that has the ability to manufacture molecules in ways that are very, very hard, of course, for academic labs and even for most companies to do. And so the idea was to bring together the best of genome editing technology, the best of clinical medicine, especially focused on rare human diseases. And this is with our partners at UCSF and with the folks in the Danaher team who are experts at downstream issues of manufacturing. And so the hope there is that we can bring those pieces together to create ways of using CRISPR that will be cost effective for patients. And frankly, we'll also create a kind of roadmap for how to do this, how to do this more efficiently. And we're kind of building the plane while we're flying it, if you know what I mean. But we're trying to really work creatively with organizations like the FDA to come up with strategies for clinical trials that will maintain safety, but also speed up the timeline.Eric Topol (18:44):And I think it's really exciting. We need that and I'm on the scientific advisory board of Danaher, a new commitment for me. And when Fyodor presented that recently, I said, wow, this is exciting. We haven't really had a path to how to get these therapies down to a much lower cost. Now, another thing that's exciting that you're involved in, which I think crosses the whole genome editing, the two most important things that I've seen in my lifetime are genome editing and AI, and they also work together. So maybe before we get into AI for drug discovery, how does AI come into play when you're thinking about doing genome editing?Jennifer Doudna (19:34):Well, the thing about CRISPR is that as a tool, it's powerful not only as a one and done kind of an approach, but it's also very powerful genomically, meaning that you can make large libraries of these guide RNAs that allow interrogation of many genes at once. And so that's great on the one hand, but it's also daunting because it generates large collections of data that are difficult to manually inspect. And in some cases, I believe really very, very difficult to analyze in traditional ways. But imagine that we have ways of training models that can look at genetic intersections, ways that genes might be affecting the behavior of not only other genes, but also how a person responds to drugs, how a person responds to their environment and allows us to make predictions about genetic outcomes based on that information. I think that's extremely exciting, and I definitely think that over the next few years we'll see that kind of analysis coming online more and more.Eric Topol (20:45):Yeah, the convergence, I think is going to be, it's already being done now, but it's just going to keep building. Now, Demis Hassabis, who one of the brilliant people in the field of AI leads the whole Google Deep Mind AI efforts now, but he formed after AlphaFold2 behaving to predict proteins, 200 million proteins of the universe. He started a company Isomorphic Labs as a way to accelerate using AI drug discovery. What can you tell us about that?Jennifer Doudna (21:23):It's exciting, isn't it? I'm on the SAB for that company, and I think it's very interesting to see their approach to drug discovery. It's different from what I've been familiar with at other companies because they're really taking a computational lens to this challenge. The idea there is can we actually predict things like the way a small molecule might interact with a particular protein or even how it might interact with a large protein complex. And increasingly because of AlphaFold and programs like that, that allow accurate prediction of structures, it's possible to do that kind of work extremely quickly. A lot of it can be done in silico rather than in the laboratory. And when you do get around to doing experiments in the lab, you can get away with many fewer experiments because you know the right ones to do. Now, will this actually accelerate the rate at which we get to approved therapeutics? I wonder about your opinion about that. I remain unsure.Editing Out Alzheimer's Risk AllelesEric Topol (22:32):Yeah. I mean, we have one great success story so far during the pandemic Baricitinib, a drug that repurposed here, a drug that was for rheumatoid arthritis, found by data mining that have a high prospects for Covid and now saves lives in Covid. So at least that's one down, but we got a lot more here too. But it, it's great that Demis recruited you on the SAB for Isomorphic because it brings in a great mind in a different field. And it goes back to one of the things you mentioned earlier is how can we get some of this genome editing into a pill someday? Wow. Now, one of the things that for personal interest, as an APOE4 carrier, I'm looking to you to fix my APOE4 and give me APOE2. How can I expect to get that done in the near future?Jennifer Doudna (23:30):Oh boy. Okay, we'll have to roll up our sleeves on that one. But it is appealing, isn't it? I think about it too. It's a fascinating idea. Could we get to a point someday where we can use genome editing as a prophylactic, not as a treatment after the fact, but as a way to actually protect ourselves from disease? And the APOE4 example is a really interesting one because there's really good evidence that by changing the type of allele that one has for the APOE gene, you can actually affect a person's likelihood of developing Alzheimer's in later life. But how do we get there? I think one thing to point out is that right now doing genome editing in the brain is, well, it's hard. I mean, it's very hard.Eric Topol (24:18):It a little bit's been done in cerebral spinal fluid to show that you can get the APOE2 switch. But I don't know that I want to sign up for an LP to have that done.Jennifer Doudna (24:30):Not quite yet.Eric Topol (24:31):But someday it's wild. It's totally wild. And that actually gets me back to that program for coronary heart disease and heart attacks, because when you're treating people with familial hypercholesterolemia, this extreme phenotype. Someday and this goes for many of these rare diseases that you and others are working on, it can have much broader applicability if you have a one-off treatment to prevent coronary disease and heart attacks and you might use that for people well beyond those who have an LDL cholesterol that are in the thousands. So that's what I think a lot of people don't realize that this editing potential isn't just for these monogenic and rare diseases. So we just wanted to emphasize that. Well, this has been a kind of wild ride through so much going on in this field. I mean, it is extraordinary. What am I missing that you're excited about?Jennifer Doudna (25:32):Well, we didn't talk about the microbiome. I'll just very briefly mention that one of our latest initiatives at the IGI is editing the microbiome. And you probably know there are more and more connections that are being made between our microbiome and all kinds of health and disease states. So we think that being able to manipulate the microbiome precisely is going to open up another whole opportunity to impact our health.Can Editing Slow the Aging Process?Eric Topol (26:03):Yeah, I should have realized that when I only mentioned two layers of biology, there's another one that's active. Extraordinary, just going back to aging for a second today, there was a really interesting paper from Irv Weissman Stanford, who I'm sure you know and colleagues, where they basically depleted the myeloid stem cells in aged mice. And they rejuvenated the immune system. I mean, it really brought it back to life as a young malice. Now, there probably are ways to do that with editing without having to deplete stem cells. And the thought about other ways to approach the aging process now that we're learning so much about science and about the immune system, which is one of the most complex ones to work in. Do you have ideas about that are already out there that we could influence the aging process, especially for those of us who are getting old?Jennifer Doudna (27:07):We're all on that path, Eric. Well, I guess the way that I think about it is I like to think that genome editing is going to pave the way to make those kinds of fundamental discoveries. I still feel that there's a lot of our genetics that we don't understand. And so, by being able to manipulate genes precisely and increasingly to look at how genes interact with each other, I think one fundamental question it relates to aging actually is why do some of us age at a seemingly faster pace than others? And it must have to do at least in part with our genetic makeup and how we respond to our environment. So I definitely think there are big opportunities there, really in fundamental research initially, but maybe later to actually change those kinds of things.Eric Topol (28:03):Yeah, I'm very impressed in recent times how much the advances are being made at basic science level and experimental models. A lot of promise there. Now, is there anything about this field that you worry about that keeps you up at night that you think, besides, we talked about that we got to get the cost down, we have to bridge health inequities for sure, but is there anything else that you're concerned about right now?Jennifer Doudna (28:33):Well, I think anytime a new technology goes into clinical trials, you worry that things may get out ahead of their skis, and there may be some overreach that happens. I think we haven't really seen that so far in the CRISPR field, which is great. But I guess I remain cautious. I think that we all saw what happened in the field of gene therapy now decades ago, but that really put a poll on that field for a long time. And so, I definitely think that we need to continue to be very cautious as gene editing continues to advance.Eric Topol (29:10):Yeah, no question. I think the momentum now is getting past that point where you would be concerned about known unknowns, if you will, things that going back to the days of the Gelsinger crisis. But it's really extraordinary. I am so thrilled to have this conversation with you and to get a chance to review where the field is and where it's going. I mean, it's exploding with promise and potential well beyond and faster. I mean, it takes a drug 17 years, and you've already gotten this into two treatments. I mean, I'm struck when you were working on this, how you could have thought that within a 10-year time span you'd already have FDA approvals. It's extraordinary.Jennifer Doudna (30:09):Yeah, we hardly dared hope. Of course, we're all thrilled that it went that fast, but I think it would've been hard to imagine it at the time.Eric Topol (30:17):Yeah. Well, when that gets simplified and doesn't require hospitalizations and bone marrow, and then you'll know you're off to the races. But look, what a great start. Phenomenal. So congratulations. I'm so thrilled to have the chance to have this conversation. And obviously we're all going to be following your work because what a beacon of science and progress and changing medicine. So thanks and give my best to my friend there at IGI, Fyodor, who's a character. He's a real character. I love the guy, and he's a good friend.Jennifer Doudna (30:55):I certainly will Eric, and thank you so much. It's been great talking with you.*******************************************************Thanks for listening and/or reading this edition of Ground Truths.I hope you found it as stimulating as I did. Please share if you did!A reminder that all Ground Truths posts (newsletter and podcast( are free without ads. Soon we'll set it up so you can select what type of posts you want to be notified about.If you wish to be a paid subscriber, know that all proceeds are donated to Scripps Research, and thanks for that—it greatly helped fund our summer internship program for 2023 and 2024.Thanks to my producer Jessica Nguyen and to Sinjun Balabanoff for audio/video support. Get full access to Ground Truths at erictopol.substack.com/subscribe

BestPodcastintheMetaverse.com Canary Cry News Talk #727 03.27.2024 - Recorded Live to 1s and 0s THREAT CRAFTING | Bridge False Flags, Cancer CRISPR, Ice Turf War Deconstructing Corporate Mainstream Media News from a Biblical Worldview Declaring Jesus as Lord amidst the Fifth Generation War! TJT Youtube (backup) Channel: https://www.youtube.com/@TheJoyspiracyTheory The Show Operates on the Value 4 Value Model: http://CanaryCry.Support Join the Supply Drop: https://CanaryCrySupplyDrop.com                   Submit Articles: https://CanaryCry.Report Submit Art: https://CanaryCry.Art Join the T-Shirt Council: https://CanaryCryTShirtCouncil.com Podcasting 2.0: https://PodcastIndex.org Resource: Index of MSM Ownership (Harvard.edu)             Resource: Aliens Demons Doc (feat. Dr. Heiser, Unseen Realm) Resource: False Christ: Will the Antichrist Claim to be the Jewish Messiah Tree of Links: https://CanaryCry.Party   This Episode was Produced By: Executive Producers Sir LX Protocol V2 Knight of the Berrean Protocol*** Felicia D***   Producers of Treasure Sir Marti K Knight of the Wrong Timeline Elle O Sir Darrin Knight of the Hungry Panda's Dame Gail Veronica D Misses TinFoilHatMan Sir Tristan Knight of the Garden Sir Morv Knight of the Burning Chariots Sir Casey the Shield Knight DrWhoDunDat Sir Scott Knight of Truth Sir Darrin Knight of the Hungry Panda's   Speakpipe Sir Ike   CanaryCry.ART Submissions Sir Dove Knight of Rusbeltia JonathanF Cassius S Sir Darrin Knight of the Hungry Panda's   MicroFictions Runksmash - The fiends begin to shake as the introduction plays, they stop fighting and untether themselves from the projectors, revealing their true demonic nature, but they can't escape before the name of Jesus escapes the speaker, and they are forced to flee.    Stephen S - With force cutbacks,  the Pittsville Police Department took on a pilot program from BuyMyTek.  A  chapGPT AI powered interactive voice response solution will replace their 911 emergency  dispatchers between the hours of midnight to 6 am.    JOLMS - Following the prolonged silence from the captain, the flight deck system (authority level 4), sends an emergency clearance request to any nearby level 3s. In the main deck, a metal compound purifier boots up at the request. Stupefied at what aid its purification could offer with such, it bounces off the requests to any level 2s and shuts down. The energy management system (level 3), also deflected the request to level 2 but granted temporary rights to the use of solar arrays. One hurdle down.   TIMESTAMPERS Jade Bouncerson, Morgan E   CanaryCry.Report Submissions JAM   REMINDERS Clankoniphius   SHOW NOTES/TIMESTAMPS Podcast = T - 4:25 from rumble HELLO, RUN DOWN 8:16 V / 3:51 P BBB/CYBERPANDEMIC 10:28 V / 6:03 P Baltimore bridge collapses; 6 presumed dead (AP) →Shipping CEO Angela Chao, Mitch McConnell's sister-in-law, was intoxicated when she drove into lake, sheriff's office says (MSN/CNN) Angela Chao connected to Baltimore group (X) Lori Allan asked Grok (X) Someone isn't so sure (X) *Presser from Synergy Marine Group, Dec 8, 2021 (SMG)   DAY JINGLE/V4V/EPs/TREASURE 48:49 V / 44:24 P   FLIPPY 1:11:27 V / 1:07:02 P Hamas blew off his arm, fellow IDF soldiers mistook him for enemy —now combat medic gets state-of-the art robotic prosthetic in NYC: ‘I will have a normal life' (NY Post)   CANCER/CRISPR/PSYOPS 1:30:07 V / 1:25:42 P Kate Middletons Cancer Diagnosis a trend (Vox) King Charles' and the princess' cancer diagnosis (People) → Charts show sharp rise in young adults getting cancer before 50 (Business Insider) Harvard 2022 cancer on the rise (news.Harvard) *A nanotechnology‐based CRISPR/Cas9 genome editing in cancer treatment (Phys.org) → 2023 Annual Threat Assessment for the Intelligence Community 2023  → 2024 Annual Threat Assessment for Intelligence Community   ANTARCTICA/CALLED IT 2:26:33 V / 2:22:08 P We can't freeze out Antarctica's national security consequences (The Hill/Opinion)   OUTRO 2:36:44 V / 2:32:19 P END

Joining host Chadi is the esteemed James LaBelle, MD, PhD, Associate Director of Pediatrics and Director of the Stem Cell and Cellular Therapy Program at the University of Chicago. Dr. LaBelle elucidates the complexities of sickle cell disease, unraveling the devastating impact it has on individuals. The episode delves into various treatments and approaches to combat this formidable disease, including bone marrow transplant and the groundbreaking use of CRISPR-Cas9 technology. LaBelle shares insights into the recent research breakthroughs, citing the remarkable research report published in the New England Journal of Medicine, showcasing the successful application of CRISPR-Cas9 for sickle cell disease. This episode serves as a gateway into the promising future of genetic therapies. Read Dr. LaBelle's publication on CRISPR-Cas9 in NEJM. https://www.nejm.org/doi/full/10.1056/NEJMoa2215643 Check out Chadi's website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/ Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA

Peter Quinn, PhD, a principal investigator and associate research scientist at Columbia University, talks to host Ben Shaberman about the promise of emerging CRISPR/Cas9 gene editing therapies, including base and prime editing approaches, for inherited retinal diseases. Dr. Quinn also reviews gene editing projects ongoing in his lab for patients with mutations in CRB1 and PRPH2.

Is it possible to make any organism fully resistant to viral infections? According to new research using E. coli from the Harvard Medical School Department of Genetics, the answer seems to be yes…eventually! Today, we're joined by one of the lead researchers in this study, Akos Nyerges. Among many fascinating developments in the fields of genetic engineering and synthetic biology, he discusses the ability to modify existing organisms to achieve desired changes, the use of new DNA building blocks to create synthetic organisms, the most challenging regions of DNA to engineer, and what to expect in the near future. Press play to discover: How an organism can be genetically engineered to have a genetic ‘firewall' from natural viral infections The difference between synthetic genomics and genetic engineering Applications of CRISPR-Cas9 gene-editing technology   The use of genetically engineered organisms in novel drug development Tune in for the full conversation, visit Home | Church Lab (harvard.edu) to learn more about Harvard's Department of Genetics, and feel free to contact Nyerges via email: Akos_Nyerges@hms.harvard.edu. Take advantage of a 5% discount on Ekster accessories by using the code FINDINGGENIUS. Enhance your style and functionality with premium accessories. Visit bit.ly/3uiVX9R to explore latest collection. Episode also available on Apple Podcasts: http://apple.co/30PvU9C

Featuring articles on an attenuated tetravalent dengue vaccine, skin antisepsis before fracture surgery, N-acetyl-L-leucine in Niemann–Pick Disease type C, in vivo CRISPR-Cas9 treatment for hereditary angioedema, and on seeing medicine more as a job than a calling; a review article on cardiac implantable electronic devices; a Clinical Problem-Solving on flipping the switch; and a Perspective article on explaining health inequities.

Discover the intricate dance of genes and CRISPR with Tak Williams as he joins me, Dr. Tiffany Montgomery, on an enlightening journey through the genetic landscape. Unlock the secrets of DNA and how it influences everything from your health to the stock market. Prepare to shatter myths and fortify your understanding of personalized medicine and species conservation, all while indulging in the excitement of scientific discovery.Venture through the annals of genetic milestones from the revelatory work of Oswald Avery. As we weave through history, the evolution of genetics unfolds, revealing its mighty hand in fields as diverse as agriculture and forensic science. Our discussions illuminate the powerful language of genes, their undeniable role in shaping our world, and the financial implications that come with these scientific breakthroughs. With each stride in genetic research, we step closer to a future where medicine is tailored to our unique genetic fabric.Finally, we grapple with the ethical conundrums that CRISPR-Cas9 presents, reflecting on the power and responsibility inherent in this ground-breaking technology. We honor the wisdom imparted on my first day at Tuskegee University, drawing parallels to our capacity for greatness and the importance of stewarding genetic advancements conscientiously. As we conclude, we inspire you to take control of your health journey, recognizing that knowledge of one's genetic makeup is a powerful ally in charting a course toward wellness.Support the show

Patrick Bet-David explains why the FDA has officially approved CRISPR gene editing as a treatment for Sickle Cell Disease, marking a historic milestone in medical science. The science behind CRISPR-Cas9, a revolutionary gene-editing tool has transformed biomedical research. Understand how it can precisely alter DNA to correct genetic defects, potentially treating a range of illnesses. As CRISPR technology advances, so does the debate over its ethical use. PBD also discusses the controversial topic of designer babies, examining the moral implications and potential societal impacts of gene editing for non-therapeutic purposes. Connect one-on-one with the right expert to get the answers you need with Minnect: https://bit.ly/3MC9IXE Get best-in-class business advice with Bet-David Consulting: https://bit.ly/40oUafz Visit VT.com for the latest news and insights from the world of politics, business and entertainment: https://bit.ly/472R3Mz Visit Valuetainment University for the best courses online for entrepreneurs: https://bit.ly/47gKVA0 Text “PODCAST” to 310-340-1132 to get the latest updates in real-time! SUBSCRIBE TO: ​⁠  @VALUETAINMENT   @PBDPodcast   @ValuetainmentShortClips   @vtsoscast   @VALUETAINMENTRUSSIAN   @ValuetainmentComedy   @bizdocpodcast   @BrandonAceto   @theunusualsuspectspodcast   @kvoncomedy  ​⁠ Want to be clear on your next 5 business moves? https://bit.ly/3Qzrj3m Join the channel to get exclusive access to perks: https://bit.ly/3Q9rSQL Download the podcasts on all your favorite platforms https://bit.ly/3sFAW4N Patrick Bet-David is the founder and CEO of Valuetainment Media. He is the author of the #1 Wall Street Journal Bestseller “Your Next Five Moves” (Simon & Schuster) and a father of 2 boys and 2 girls. He currently resides in Ft. Lauderdale, Florida. --- Support this podcast: https://podcasters.spotify.com/pod/show/valuetainment/support

In this 180th episode of the Live Healthy Be Well podcast Jeffrey is in front of a Zoom audience answering questions and also discussing the new threat, GMO 2.0.  GMO 2.0 mainly includes CRISPR-Cas9 and the ease with which regular, non-scientific citizens can create their own strains of genetically modified microbes. These microbes have the potential to alter the genetic structure of other microbes that have evolved over millions of years. This could wreak havoc on our environment and our own gut microbiome. For more information on GMO 2.0 please watch our short documentaries, "Don't Let the Gene Out of the Bottle" and  "7 Reasons Why Gene Editing is Dangerous and Unpredictable" The Institute for Responsible Technology is working to protect you & the World from the release of genetically engineered microbes.  To find out exactly how we do this and to subscribe to our newsletter visit https://www.responsibletechnology.org/ While there please visit the Take Action page: https://responsibletechnology.org/takeaction/ to learn what you can do right now to stem the tide of these dangerous releases. Watch our short film, "7 Reasons Why Gene Editing is Dangerous and Unpredictable" Watch the film: Secret Ingredients Watch "Don't Let the Gene Out of the Bottle" Get the book: "Seeds of Deception" IG @irtnogmos Facebook @responsibletechnology YouTube @TheInstituteforResponsibleTechinology Twitter @TheInstituteforResponsibleTechnology

We have a new podcast! It's called Universe Of Art, and it features conversations with artists who use science to bring their creations to the next level. Listen on Apple Podcasts, Spotify, or wherever you get your podcasts.    A See-Through Squid Success Story Adult octopuses have about 500 million neurons, which is about as many neurons as a dog. Typically, more neurons means a more intelligent and complex creature. But it's a bit more complicated than that. Unlike dogs, or even humans, octopuses' neurons aren't concentrated in their brains—they're spread out through their bodies and into their arms and suckers, more like a “distributed” mind. (Scientists still haven't quite figured out exactly why this is.) And that's just the tip of the iceberg, in terms of unanswered cephalopod questions. Now, researchers have successfully bred a line of albino squid that were first engineered using CRISPR-Cas9 gene editing technology, creating a see-through squid. Their unique transparency allows scientists to more easily study their neural structure, and a whole lot more. SciFri experiences manager Diana Plasker talks with Joshua Rosenthal, senior scientist at the University of Chicago's Marine Biological Laboratory, based in Woods Hole, Massachusetts, about this see-through squid success story. When Eye-Grabbing Results Just Don't Pan Out You know the feeling — you see a headline in the paper or get an alert on your phone about a big scientific breakthrough that has the potential to really change things. But then, not much happens, or that news turns out to be much less significant than the headlines made it seem. Journalists are partially to blame for this phenomenon. But another guilty culprit is also the scientific journals, and the researchers who try to make their own work seem more significant than the data really supports in order to get published. Armin Alaedini, an assistant professor of medical sciences at Columbia University Medical Center in New York, recently co-authored a commentary on this topic published in The American Journal of Medicine. He joins Ira and Ivan Oransky — co-founder of Retraction Watch and a medical journalism professor and Distinguished Writer In Residence at New York University — to talk about the tangled world of scientific publishing and the factors that drive inflated claims in publications.     How Art Can Help Treat Dementia And Trauma We might intrinsically know that engaging with and making art is good for us in some way. But now, scientists have much more evidence to support this, thanks in part to a relatively new field called neuroaesthetics, which studies the effects that artistic experiences have on the brain. A new book called Your Brain On Art: How The Arts Transform Us, dives into that research, and it turns out the benefits of the arts go far beyond elevating everyday life; they're now being used as part of healthcare treatments to address conditions like dementia and trauma. Universe of Art host D. Peterschmidt sits down with the authors of the book, Susan Magsamen, executive director of the International Arts + Mind Lab at the Pederson Brain Science Institute at Johns Hopkins University, and Ivy Ross, vice president of design for hardware products at Google, to talk about what we can learn from neuroaesthetic studies, the benefits of a daily arts practice, and the kinds of art they both like making.   Testing Mars Rovers In Utah's Red Desert Take a 20-minute drive down Cow Dung Road, outside of Hanksville, Utah, and you'll stumble across the Mars Desert Research Station. This cluster of white buildings—webbed together by a series of covered walkways—looks a little alien, as does the red, desolate landscape that surrounds it. “The ground has this crust that you puncture through, and it makes you feel like your footprints are going to be there for a thousand years,” said Sam Craven, a senior leading the Brigham Young University team here for the University Rover Challenge. “Very bleak and dry, but very beautiful also.” This remote chunk of Utah is a Mars analogue, one of roughly a dozen locations on Earth researchers use to test equipment, train astronauts and search for clues to inform the search for life on other planets. While deployed at the station, visiting scientists live in total isolation and don mock space suits before they venture outside. To read the rest, visit sciencefriday.com.   To stay updated on all-things-science, sign up for Science Friday's newsletters. Transcripts for each segment will be available the week after the show airs on sciencefriday.com.